In 2023, Ionis Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Ionis Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ionis Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
In 2023, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals amounted to 5,483 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Ionis Pharmaceuticals increased by 27.6%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
In 2023, the total Scope 1 emissions of Ionis Pharmaceuticals were 2,695 metric tons of CO₂ equivalent (tCO₂e). a
Since 2021, Ionis Pharmaceuticals's Scope 1 emissions have increased by 5.03%, reflecting a rising long-term trend in Scope 1 emissions over time. a
Compared to the previous year (2022), Ionis Pharmaceuticals's Scope 1 emissions increased by 9.73%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
In 2023, Ionis Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 2,788 tCO₂e using the market-based method. a
Since 2021, Ionis Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have increased by 35.87%, reflecting a rising long-term trend in Scope 2 emissions over time. a
Compared to the previous year (2022), Ionis Pharmaceuticals's Scope 2 emissions (Market-Based) rose by 51.44% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a
In 2023, Ionis Pharmaceuticals reported its Scope 2 emissions using the market-based method. a